- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1775KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 703KB)
Olaparib – November 2021
Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
4 March 2022